Final EMPEROR-Preserved Data Show Jardiance Led to Statistically Significant Improvement in Heart Failure Outcomes in Adults with Preserved Ejection Fraction

Final EMPEROR-Preserved Data Show Jardiance Led to Statistically Significant Improvement in Heart Failure Outcomes in Adults with Preserved Ejection Fraction

Boehringer Ingelheim and Eli Lilly presented full results from the landmark EMPEROR-Preserved Phase III trial, demonstrating that empagliflozin showed a 21 percent relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure in adults with heart failure with preserved ejection fraction (HFpEF) compared with placebo. The benefit was independent of ejection fraction or diabetes status. The results were presented at the European Society of Cardiology (ESC) Congress 2021 and published in The New England Journal of Medicine. These results establish empagliflozin as the first treatment to significantly improve outcomes for the full spectrum of heart failure patients.

EMPEROR-Preserved included 5,988 patients with heart failure. Of these, 4,005 had a left ventricular ejection fraction (LVEF) of 50 percent or above and 1,983 had a LVEF below 50 percent. The patients were randomly assigned to empagliflozin 10 mg (n=2,997) or placebo (n=2,991) once daily. In addition to meeting the primary endpoint, key secondary endpoint analyses showed that empagliflozin also reduced the relative risk of first and ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee